Prognostic significance of OX40
CD4
CD8
OX40
Small-cell lung cancer
survival
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
16
10
2021
Statut:
epublish
Résumé
OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of various organs. In this study, we collected formalin-fixed paraffin-embedded tumor samples from 124 patients with small-cell lung cancer (SCLC) who had undergone surgery. We analyzed the expression profiles of OX40 and other relevant molecules, such as CD4, CD8, and Foxp3, in tumor stroma and cancer nest using immunohistochemistry and investigated their association with survival. High infiltration of OX40
Identifiants
pubmed: 34552823
doi: 10.1080/2162402X.2021.1971430
pii: 1971430
pmc: PMC8451465
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1971430Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
Dr. Hiroshi Yokouchi received grants from AbbVie, AstraZeneca, and Chugai Pharmaceutical, in addition to honoraria for lectures from AstraZeneca and Chugai Pharmaceutical. Dr. Satoshi Oizumi received grants from AstraZeneca and Chugai Pharmaceutical, in addition to honoraria for lectures from AstraZeneca, Chugai Pharmaceutical, and Nippon Kayaku. Dr. Fumihiro Tanaka received grants from Chugai Pharmaceutical, in addition to payment for lectures from AstraZeneca and Chugai Pharmaceutical. Dr. Masao Harada received grants from AstraZeneca and Chugai Pharmaceutical. The other authors declare no conflicts of interest.
Références
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98
pubmed: 23307984
Cell Rep. 2019 Nov 19;29(8):2164-2174.e5
pubmed: 31747591
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33651881
Nat Med. 2018 Nov;24(11):1645-1648
pubmed: 30401867
J Thorac Oncol. 2020 Aug;15(8):1281-1297
pubmed: 32522713
Cancer Sci. 2008 Feb;99(2):361-7
pubmed: 18201271
J Immunol. 2004 Apr 15;172(8):4821-5
pubmed: 15067059
J Thorac Oncol. 2018 Aug;13(8):1113-1120
pubmed: 29704674
Oncotarget. 2015 Nov 10;6(35):37588-99
pubmed: 26439988
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Nature. 2020 Nov;587(7835):619-625
pubmed: 33208946
Front Immunol. 2012 Mar 21;3:51
pubmed: 22566933
Oncotarget. 2017 May 3;8(37):62312-62329
pubmed: 28977947
Onco Targets Ther. 2020 Jul 03;13:6475-6483
pubmed: 32753888
Sci Rep. 2019 Feb 22;9(1):2636
pubmed: 30796310
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Clin Transl Immunology. 2016 Apr 15;5(4):e70
pubmed: 27195113
Clin Cancer Res. 2000 May;6(5):1875-81
pubmed: 10815910
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
ESMO Open. 2020 Feb;5(1):
pubmed: 32392177
Nat Med. 2021 Mar;27(3):504-514
pubmed: 33603241
Cancer Res. 2018 Oct 1;78(19):5492-5503
pubmed: 30206177
Annu Rev Pathol. 2010;5:193-221
pubmed: 19824828
Eur J Cancer. 2016 Jan;52:50-66
pubmed: 26645943
Onco Targets Ther. 2019 Nov 21;12:10043-10055
pubmed: 31819500
Immunol Cell Biol. 2014 Jul;92(6):475-80
pubmed: 24732076
Oncoimmunology. 2018 Mar 6;7(4):e1404214
pubmed: 29632718
Mol Oncol. 2020 Sep;14(9):1947-1965
pubmed: 32506804
Lung Cancer. 2017 Oct;112:75-80
pubmed: 29191604
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
Front Immunol. 2020 Dec 14;11:594609
pubmed: 33381115
Cancer Res. 2006 Jun 1;66(11):5527-36
pubmed: 16740684
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Cancer Sci. 2020 Oct;111(10):3426-3434
pubmed: 32726495
Front Oncol. 2015 Feb 16;5:34
pubmed: 25763356
Mol Immunol. 2017 Mar;83:13-22
pubmed: 28092803
Cancer Res. 2013 Dec 15;73(24):7189-7198
pubmed: 24177180
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Lung Cancer. 2015 Dec;90(3):548-53
pubmed: 26604032
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Immunother Cancer. 2019 Dec 16;7(1):351
pubmed: 31843013
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419